Follow-up findings from the phase 3 OlympiAD trial support the possibility of long-term survival benefit with olaparib when used in the first-line metastatic setting.
Medscape Medical News
Follow-up findings from the phase 3 OlympiAD trial support the possibility of long-term survival benefit with olaparib when used in the first-line metastatic setting.
Medscape Medical News
